Anixa Biosciences (ANIX) Operating Leases (2020 - 2026)
Anixa Biosciences' (ANIX) quarterly Operating Leases came in at $140000.0 in Q2 2026, down 23.91% YoY from $184000.0 in Q2 2025, and down 14.11% on a QoQ basis from $163000.0 in Q4 2025.
Anixa Biosciences (ANIX) Operating Leases (2020 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 7 years of Operating Leases data on file, last reported at $140000.0 in Q2 2026.
- Quarterly Operating Leases fell 23.91% year-over-year to $140000.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $140000.0 (down 23.91% YoY) and the FY2025 annual result came in at $163000.0, down 19.7% from the prior year.
- Operating Leases slipped to $140000.0 in Q2 2026, from $163000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $241000.0 in Q2 2022 to a low of $123000.0 in Q4 2023.
- A 5-year average of $187000.0 and a median of $187000.0 in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases jumped 2086.05% — and 2023, when it slipped 29.71%.
- Tracing ANIX's Operating Leases over 5 years: stood at $175000.0 in 2022, then fell by 29.71% to $123000.0 in 2023, then jumped by 65.04% to $203000.0 in 2024, then declined by 19.7% to $163000.0 in 2025, then slipped by 14.11% to $140000.0 in 2026.
- The last three Operating Leases figures came in at $140000.0 (Q2 2026), $163000.0 (Q4 2025), and $174000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Anixa Biosciences | 125.30 Mn | 125.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 140,000.00 |
| Oct 31, 2025 | 163,000.00 |
| Jul 31, 2025 | 174,000.00 |
| Apr 30, 2025 | 184,000.00 |
| Jan 31, 2025 | 194,000.00 |
| Oct 31, 2024 | 203,000.00 |
| Jul 31, 2024 | 237,000.00 |
| Apr 30, 2024 | 149,000.00 |
| Jan 31, 2024 | 162,000.00 |
| Oct 31, 2023 | 123,000.00 |
| Jul 31, 2023 | 187,000.00 |
| Apr 30, 2023 | 198,000.00 |
| Jan 31, 2023 | 209,000.00 |
| Oct 31, 2022 | 175,000.00 |
| Jul 31, 2022 | 231,000.00 |
| Apr 30, 2022 | 241,000.00 |
| Jan 31, 2022 | 209,000.00 |
| Oct 31, 2021 | 220,000.00 |
| Jul 31, 2021 | 10,567.00 |
| Apr 30, 2021 | 25,964.00 |